Systematic Review: anti-interleukin-13 or anti-interleukin-4 agents may be appropriate for adults with moderate-to-severe uncontrolled asthma who have not responded to other treatments.

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma – Cochrane Library

Summary: Anti-interleukin-13 or anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma – Cochrane Library

Commentary on Twitter (thread – click for more)

Lead author David Evans said “Approximately five to ten percent of people with asthma experience symptoms that are severe or difficult-to-treat… [1/3] pic.twitter.com/Nw606oSrX0

— CochraneAirways (@CochraneAirways) October 19, 2021